Fierce Biotech2d
Opthea's eye disease drug defeated by Eylea in phase 3, leaving biotech to mull future
Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...
pharmaphorum1d
Phase 3 readout puts Opthea at risk of insolvency
Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet ...
Opthea cut to Market Perform at Leerink on failed sozinibercept trial
Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...
Opthea’s survival in doubt after late-stage eye drug trial fails
Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...
pharmaphorum1d
FDA clears Roche's Susvimo implant for eye disease wet AMD
The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).
Ophthalmology Times1d
Angiogenesis and the eye: A Journey to unlock the secrets of blood vessel growth
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...